One of the largest manufacturing facilities for active pharmaceutical ingredients (APIs) in Russia will soon be built in the Bryansk region of the country, according to the local Ministry of Health, reports The Pharma Letter’s local correspondent. 20 August 2018
Japanese drugmaker Takeda Pharmaceutical plans to invest up to $10 million in the establishment of production of an innovative orphan drug for multiple myeloma patients, according to some Russian media reports. 20 August 2018
In an Expert View piece, Charlie Johnson, chief executive of UK biotech ADC Bio, takes a look at a product class that is still in its infancy. 16 August 2018
UK biopharma firm PureTech Health has announced the appointment of Dr Steven Paul, as chief executive of its affiliate, Karuna Pharmaceuticals. 15 August 2018
Following the resignation of Dr Andrew Cheng, chief medical officer of US biotech major Gilead Sciences, the company has announced two promotions. 15 August 2018
The doors appear to be opening. In what is being seen as a major positive for the Indian pharma industry, the US Food and Drug Administration is working on an action plan to import drugs. Addressing price hikes, the import of drugs is expected to be limited to the drugs that are off-patent, reports The Pharma Letter’s India correspondent. 13 August 2018
Namir Hassan has been named chief scientific officer of Zelluna Immunotherapy, a privately-held Norwegian biotech specializing in T-cell receptor (TCR) immunotherapies. 13 August 2018
“The Russian pharma market is like a huge ocean. If you know who lives in the ocean and what sort of currents the ocean has, then it is all simple and understandable.” 10 August 2018
Leading domestic drugmakers in Russia have called on the national government to introduce additional restrictions on the participation of foreign companies in public procurements in the country, reports The Pharma Letter’s Russia correspondent. 10 August 2018
The government of Russia’s capital Moscow has announced a record tender for the current year, which involves the establishment of production and further supplies of drugs on the total sum of 22.6 billion roubles ($342 million) by 2028, reports The Pharma Letter’s local correspondent. 9 August 2018
In an Expert View piece, Mark Davison, head of operations in the European Union for software company RFXCEL, outlines everything marketing authorization holders need to know and what you need to do for a seamless serialization process – before regulators remove your right to trade. 8 August 2018
No need for anxiety — that’s the line at the launch of a new white paper from contract research organization IQVIA, tackling the uncertainty facing UK biopharma ahead of the country’s departure from the European Union. 7 August 2018
Alzheon, a privately-held American biopharmaceutical company, has announced its hiring of former IVAX president Neil Flanzraich as vice chairman of the board. 6 August 2018
In an Expert View piece, Doug Robinson, principal at IP firm Harness Dickey, considers some of the challenges facing the pharma industry in the field of patent rights. 3 August 2018
“The innovation and transformative potential that this pipeline holds really give us a lot of confidence that we are going to emerge as a strong player in the oncology space.” 3 August 2018
CAR-T therapy company Cellectis announced on Friday that Stefan Scherer, vice president and global lead for early development and innovation at Novartis, would join the company in a leadership role. 3 August 2018
USA-headquartered oncology specialist BeyondSpring has named Richard Daly its chief operating officer to lead the transition to commercialization of the chemotherapy-induced neutropenia (CIN) drug plinabulin. 2 August 2018
Privately-owned UK biotech Cell Medica has named Chris Nowers its new chief executive after its founder and former leader Gregg Sando stepped down. 1 August 2018
Cheryl Schwartz has brought her time with drug giant Pfizer to an end by becoming a vice president with German drugmaker Merck KGaA, where she will head up US fertility and endocrinology. 1 August 2018
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024